Dapagliflozin for patients with heart failure and reduced ejection fraction

JAAPA. 2022 Sep 1;35(9):51-53. doi: 10.1097/01.JAA.0000840504.15807.70.

Abstract

The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.

MeSH terms

  • Adult
  • Benzhydryl Compounds / therapeutic use
  • Glucosides / therapeutic use
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume
  • Ventricular Dysfunction, Left* / chemically induced

Substances

  • Benzhydryl Compounds
  • Glucosides
  • dapagliflozin